Captrust Financial Advisors Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Captrust Financial Advisors raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,130 shares of the biopharmaceutical company’s stock after purchasing an additional 296 shares during the quarter. Captrust Financial Advisors’ holdings in Regeneron Pharmaceuticals were worth $9,597,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after purchasing an additional 59,769 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after purchasing an additional 96,266 shares in the last quarter. Finally, TD Asset Management Inc lifted its stake in shares of Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after purchasing an additional 82,034 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $750.22 on Monday. The business has a fifty day moving average of $905.64 and a two-hundred day moving average of $1,019.64. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $82.44 billion, a price-to-earnings ratio of 18.57, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15.

Wall Street Analysts Forecast Growth

Several analysts recently commented on REGN shares. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Finally, Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.